Valeant's 2015 price hikes so far: 56 meds and counting

Valeant ($VRX) may be in the spotlight for hiking prices on Isuprel and Nitropress, a pair of meds it acquired this year from Marathon Pharmaceuticals. But they're hardly alone: The Canadian drugmaker has jacked up prices on 54 other meds so far this year, increasing them by an average of 65.6%, according to a Deutsche Bank analysis. More from FiercePharma